Drug-induced liver injury: Is chronic liver disease a risk factor and a clinical issue?

Expert Opin Drug Metab Toxicol

c Pharmacovigilance Consultancy , Paris , France.

Published: April 2017

AI Article Synopsis

  • Clinicians managing patients with chronic liver disease often face uncertainty about the risk of drug-induced liver injury (DILI) from treatments.
  • The analysis focused on various medications, including statins and antivirals, in patients with conditions like fatty liver disease and cirrhosis, highlighting the complexity of drug therapy in those with decompensated liver cirrhosis.
  • While most drugs are generally well tolerated in patients with non-cirrhotic chronic liver disease, careful consideration is needed for certain therapies, and more prospective studies are needed to confirm these findings.

Article Abstract

Clinicians and practitioners caring for patients with chronic liver disease are often unsure whether drug therapy is a hazard that increases their patient's risk for drug-induced liver injury (DILI). Areas covered: We searched for reports of drug induced liver injury, both idiosyncratic and intrinsic, in patients with chronic liver disease including non-alcoholic and alcoholic liver disease, and cirrhosis. Reports we analyzed include statin treatment in patients with fatty liver, acetaminophen use in alcoholic fatty liver, antituberculous drugs in patients with tuberculosis and viral hepatitis, antiviral medications in hepatitis and antiretroviral medications in HIV/AIDS. The most challenging cases we found are drug therapy in patients with decompensated liver cirrhosis. Expert opinion: We identified many case reports and case series discussing a potential increased risk of DILI in patients with pre-existing liver disease. However, most of these reports were retrospective and ambiguous. With few exceptions, we conclude that drugs seem to be well tolerated by the majority of patients with pre-existing, non-cirrhotic chronic liver diseases. Special care is needed for some therapies, however, including antiviral therapy in chronic hepatitis B and C and in decompensated liver cirrhosis with impaired drug metabolism. Prospective studies are warranted to valid our conclusions.

Download full-text PDF

Source
http://dx.doi.org/10.1080/17425255.2017.1252749DOI Listing

Publication Analysis

Top Keywords

liver disease
20
chronic liver
16
liver injury
12
liver
12
drug-induced liver
8
patients chronic
8
drug therapy
8
fatty liver
8
decompensated liver
8
liver cirrhosis
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!